## IN THE CLAIMS

Please cancel without prejudice all of the pending claims 1-60.

Please add the following additional claims:

A method of immunizing a mammal against infection by group A Streptococcal bacteria comprising administering to an individual an immunogenic amount of the polysaccharide of formula (I)

$$[\rightarrow 2)$$
- $\alpha$ -L-Rhap- $(1\rightarrow 3)$ - $\alpha$ -L-Rhap- $(1\rightarrow)$ n-R

 $\uparrow$ 
 $\uparrow$ 
 $\beta$ -D-GlcpNAc

**(I)** 

wherein R is a terminal reducing L-rhamnose or D-GlcpNAc and n is a number from about 3 to about 30, and wherein the polysaccharide is covalently linked to protein.

- 62. The method of immunizing according to claim 61 wherein the group A polysaccharide has a molecular weight of about 10 Kd.
- 63. The method of immunizing according to claim 62 wherein the group A polysaccharide is administered in a dosage amount of about  $0.10~\mu g$  to about  $10~\mu g$  per kilogram of body weight.
- 64. The method of immunizing according to claim 61 wherein the protein is linked to the polysaccharide through a secondary amine bond.
- 65. The method of immunizing according to claim 64 wherein the protein is any native or recombinant bacterial protein.
- 66. The method of immunizing according to claim 65 wherein the protein is selected from the group consisting of tetanus toxoid, cholera toxin, diphtheria toxoid, and CRM<sub>197</sub>.

300 434 67. The method of immunizing according to claim 66 wherein the protein of the

-2-

Express Mail Label No.: EI086496261US

## polysaccharide-protein conjugate is tetanus toxoid.

- 68. The method of immunizing according to claim 63 wherein polysaccharide is administered with a carrier selected from the group consisting of saline, Ringer's solution and phosphate buffered saline.
- 69. The method of immunizing according to claim 68 wherein the polysaccharide is administered with an adjuvant.
- 70. The method of immunizing according to claim 69 wherein the adjuvant is selected from the group consisting of aluminum hydroxide, aluminum phosphate, monophosphoryl lipid A, QS21 and stearyl vrosine.
- 71. The method of immunizing according to claim 61 wherein the mammal is human.
  - 72. The method of immunizing according to claim 71 wherein the human is a child.
- 73. An immune composition for conferring passive immunity against group A Streptococcal bacteria in humans, said immune composition comprising opsonic antibodies which are bactericidal in the presence of complement and phagocytes and wherein said antibodies are a) obtained from a human; b) bind to polysaccharide of group A Streptococcal bacteria of formula (I)

[→2)-
$$\alpha$$
-L-Rhap-(1→3)- $\alpha$ -L-Rhap-(1→]<sub>n</sub>-R

$$\uparrow$$
1

 $\beta$ -D-GlcpNAc

wherein R is a terminal reducing L-rhamnose or D-GlcpNAc and n is a number from about 3 to about 30; and c) are present in said composition in an immunoprotective amount.

- 74. The immune composition according to claim 73 wherein the antibodies are present in serum, a gamma globulin fraction or a purified antibody preparation.
- 75. A method of conferring passive immunity against group A Streptococcal bacteria comprising administering to a human a pharmaceutical composition comprising

. 0

ŧ

Ŀ

7... 

Ú

ü

opsonic antibodies which are bactericidal in the presence of complement and phagocytes and wherein said opsonic antibodies are a) obtained from a human and b) bind to polysaccharide of group A Streptococcal bacteria of formula (I)

[→2)-
$$\alpha$$
-L-Rhap-(1→3)- $\alpha$ -L-Rhap-(1→]<sub>n</sub>-R

$$\uparrow$$
1

 $\beta$ -D-GlcpNAc

wherein R is a terminal reducing L-rhamnose or D-GlcpNAc and n is a number from about 3 to about 30; and c) are present in said pharmaceutical composition in an immunoprotective amount.

- The method according to claim 75 wherein said opsonic antibodies are isolated 76. from sera having a titer greater than about 40,000.
- The method according to claim 75 wherein said opsonic antibodies are isolated 77. from sera having a titer greater than about 75,000.
- 78. The method according to claim 75 wherein said opsonic antibodies are isolated from sera having a titer greater than about 100,000.
- The method according to claim 76 wherein said opsonic antibodies are isolated 79. from sera having a titer greater than about 200,000.

## REMARKS

Applicants appreciate the Examiner's time for the constructive interview.

Support for the new claims is shown below:

Support for claims 61-72 is found in the specification, for example, at page 5, lines 19-35.

Claims 73-79 find support throughout the specification. For example, the specification discloses at least two sources of antibodies demonstrated to be bactericidal in the presence of